← Back to Screener
Vivos Therapeutics, Inc. Common Stock (VVOS)
Price$1.01
Favorite Metrics
Price vs S&P 500 (26W)-77.53%
Price vs S&P 500 (4W)-29.65%
Market Capitalization$13.14M
All Metrics
Book Value / Share (Quarterly)$0.31
P/TBV (Annual)3.33x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-3.81%
Cash Flow / Share (Quarterly)$-1.86
Price vs S&P 500 (YTD)-56.15%
Gross Margin (TTM)55.74%
Net Profit Margin (TTM)-98.77%
EPS (TTM)$-1.88
10-Day Avg Trading Volume0.59M
EPS Excl Extra (TTM)$-1.88
Revenue Growth (5Y)5.70%
EPS (Annual)$-2.22
ROI (Annual)-140.01%
Gross Margin (Annual)60.00%
Net Profit Margin (5Y Avg)-106.76%
Cash / Share (Quarterly)$0.37
Revenue Growth QoQ (YoY)75.73%
ROA (Last FY)-72.86%
Revenue Growth TTM (YoY)18.76%
EBITD / Share (TTM)$-1.79
ROE (5Y Avg)-818.50%
Operating Margin (TTM)-94.26%
Cash Flow / Share (Annual)$-2.25
P/B Ratio5.19x
P/B Ratio (Quarterly)10.12x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)1.09x
Net Interest Coverage (TTM)-602.00x
ROA (TTM)-87.44%
EPS Incl Extra (Annual)$-2.22
Current Ratio (Annual)1.50x
Quick Ratio (Quarterly)0.70x
3-Month Avg Trading Volume0.18M
52-Week Price Return-53.17%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.04
P/S Ratio (Annual)0.87x
Asset Turnover (Annual)0.98x
52-Week High$7.95
Operating Margin (5Y Avg)-112.12%
EPS Excl Extra (Annual)$-2.22
CapEx CAGR (5Y)25.84%
26-Week Price Return-68.78%
Quick Ratio (Annual)1.34x
13-Week Price Return-53.39%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)0.78x
Enterprise Value$18.948
Revenue / Share Growth (5Y)-28.72%
Asset Turnover (TTM)0.89x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-74.09%
Cash / Share (Annual)$1.06
3-Month Return Std Dev88.28%
Gross Margin (5Y Avg)67.35%
Net Income / Employee (TTM)$-0
ROE (Last FY)-140.01%
EPS Basic Excl Extra (Annual)$-2.22
Receivables Turnover (TTM)13.38x
Total Debt / Equity (Quarterly)3.51x
EPS Incl Extra (TTM)$-1.88
Receivables Turnover (Annual)47.57x
ROI (TTM)-187.51%
P/S Ratio (TTM)0.76x
Pretax Margin (5Y Avg)-106.76%
Revenue / Share (Annual)$2.99
Tangible BV / Share (Annual)$1.29
Price vs S&P 500 (52W)-88.26%
Year-to-Date Return-52.01%
5-Day Price Return-20.16%
EPS Normalized (Annual)$-2.22
ROA (5Y Avg)-96.22%
Net Profit Margin (Annual)-74.09%
Month-to-Date Return-17.45%
Cash Flow / Share (TTM)$-13.48
EBITD / Share (Annual)$-2.10
Operating Margin (Annual)-74.32%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-816.53%
LT Debt / Equity (Quarterly)3.31x
EPS Basic Excl Extra (TTM)$-1.88
P/TBV (Quarterly)71.19x
P/B Ratio (Annual)3.18x
Pretax Margin (TTM)-98.77%
Book Value / Share (Annual)$1.35
Price vs S&P 500 (13W)-56.26%
Beta6.61x
Revenue / Share (TTM)$1.58
ROE (TTM)-351.28%
52-Week Low$0.96
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.00
4.00
4.00
4.00
Industry Peers — Surgical & Medical Instruments(108)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
VVOSVivos Therapeutics, Inc. Common Stock | 0.76x | 5.70% | 55.74% | -94.26% | $1.01 |
SYKStryker Corporation | 5.17x | 11.84% | 64.57% | 19.43% | $338.34 |
BSXBoston Scientific Corp. | 4.58x | 15.16% | 69.01% | 18.00% | $60.99 |
MMM3M Company | 3.21x | -4.97% | 39.92% | 18.55% | $151.40 |
MDLNMedline Inc. Class A common stock | 2.20x | — | 26.44% | 7.78% | $48.26 |
BDXBecton, Dickinson and Co. | 2.06x | 6.32% | 46.42% | 12.15% | $158.64 |
RMDResMed Inc. | 6.07x | 11.72% | 60.85% | 33.70% | $226.14 |
DXCMDexCom, Inc. | 5.33x | 19.33% | 62.09% | 19.56% | $64.62 |
WSTWest Pharmaceutical Services, Inc. | 6.29x | 7.44% | 35.91% | 19.03% | $278.00 |
PODDInsulet Corporation | 5.19x | 24.53% | 71.63% | 12.92% | $200.87 |
PENPenumbra, Inc. | 9.24x | 20.16% | 67.14% | 13.48% | $329.71 |
About
Vivos Therapeutics develops a non-invasive oral appliance system for treating mild-to-moderate obstructive sleep apnea, combining customized devices with proprietary clinical protocols. The approach offers patients a lower-cost alternative to surgery or pharmaceuticals. The therapy is delivered through a network of specially trained dentists working with medical professionals, creating a differentiated market position in sleep disorder treatment.